841 related articles for article (PubMed ID: 21353113)
1. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
Pan F; Peng S; Fleurence R; Linnehan JE; Knopf K; Kim E
Clin Ther; 2010 Dec; 32(14):2444-56. PubMed ID: 21353113
[TBL] [Abstract][Full Text] [Related]
2. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
3. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
Lübbert M; Suciu S; Baila L; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Beeldens F; Muus P; Pflüger KH; Coens C; Hagemeijer A; Eckart Schaefer H; Ganser A; Aul C; de Witte T; Wijermans PW
J Clin Oncol; 2011 May; 29(15):1987-96. PubMed ID: 21483003
[TBL] [Abstract][Full Text] [Related]
4. A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromes.
Gidwani R; Khan ZM; Fenaux P; Beach CL; Pashos CL
J Med Econ; 2012; 15(1):145-54. PubMed ID: 21988635
[TBL] [Abstract][Full Text] [Related]
5. [Cost-effectiveness analysis of azacitidine for myelodysplastic syndromes in Japan].
Tomonaga M; Kamae I
Rinsho Ketsueki; 2012 Mar; 53(3):310-7. PubMed ID: 22499047
[TBL] [Abstract][Full Text] [Related]
6. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.
Kantarjian H; Issa JP; Rosenfeld CS; Bennett JM; Albitar M; DiPersio J; Klimek V; Slack J; de Castro C; Ravandi F; Helmer R; Shen L; Nimer SD; Leavitt R; Raza A; Saba H
Cancer; 2006 Apr; 106(8):1794-803. PubMed ID: 16532500
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
Zeng X; Peng L; Li J; Chen G; Tan C; Wang S; Wan X; Ouyang L; Zhao Z
Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269
[TBL] [Abstract][Full Text] [Related]
8. Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.
Tikhonova IA; Hoyle MW; Snowsill TM; Cooper C; Varley-Campbell JL; Rudin CE; Mujica Mota RE
Pharmacoeconomics; 2017 Mar; 35(3):363-373. PubMed ID: 27752999
[TBL] [Abstract][Full Text] [Related]
9. The euphoria of hypomethylating agents in MDS and AML: is it justified?
Sekeres MA
Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
[TBL] [Abstract][Full Text] [Related]
10. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.
Xie M; Jiang Q; Xie Y
Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):22-8. PubMed ID: 25042977
[TBL] [Abstract][Full Text] [Related]
11. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
Estey EH
Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Cashen AF; Shah AK; Todt L; Fisher N; DiPersio J
Cancer Chemother Pharmacol; 2008 Apr; 61(5):759-66. PubMed ID: 17564707
[TBL] [Abstract][Full Text] [Related]
13. Myelodysplastic syndromes: health care management considerations.
Kogan AJ; Dunn JD
Manag Care; 2009 Nov; 18(11 Suppl 9):25-8; discussion 28-9. PubMed ID: 20085114
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands.
Stam WB; O'Sullivan AK; Rijnders B; Lugtenburg E; Span LF; Janssen JJ; Jansen JP
Eur J Haematol; 2008 Dec; 81(6):467-74. PubMed ID: 18754857
[TBL] [Abstract][Full Text] [Related]
15. Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG).
Becker H; Suciu S; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Muus P; Pflüger KH; Hagemeijer A; Schaefer HE; Fiaccadori V; Baron F; Ganser A; Aul C; de Witte T; Wijermans PW; Lübbert M
Ann Hematol; 2015 Dec; 94(12):2003-13. PubMed ID: 26400023
[TBL] [Abstract][Full Text] [Related]
16. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system.
Matter-Walstra K; Joerger M; Kühnel U; Szucs T; Pestalozzi B; Schwenkglenks M
Value Health; 2012 Jan; 15(1):65-71. PubMed ID: 22264973
[TBL] [Abstract][Full Text] [Related]
18. The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
Greenberg PL; Cosler LE; Ferro SA; Lyman GH
J Natl Compr Canc Netw; 2008 Oct; 6(9):942-53. PubMed ID: 18926103
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
20. Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis.
Vaughn JE; Othus M; Powell MA; Gardner KM; Rizzuto DL; Hendrie PC; Becker PS; Pottinger PS; Estey EH; Walter RB
JAMA Oncol; 2015 Nov; 1(8):1120-7. PubMed ID: 26355382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]